Search
  • Jill Forrest, President Oncology Strategies

Measuring the return from pharmaceutical innovation 2017: Deloitte Report shows declining ROI


The eighth annual pharmaceutical innovation study by the Deloitte Centre for Health Solutions looks at the state of R&D in the biopharma industry and estimates the return on investment that 12 large cap biopharma companies may expect to achieve. The report also includes an extension cohort of four mid-tier biopharma companies.

Click here for link to full report.

#RD #pharmaceuticals #Deloitte #oncologyresearch

25 views

info@oncologystrategies.com   |   Overland Park, KS 66223

  • Facebook Basic Black
  • Twitter Basic Black
  • Black Instagram Icon